Study to Analyze safety, effectiveness and compliance of erythropoietin therapy using WEPOXÂ® Dispopen, A new delivery device, in the management of CKD Anemia

Prospective Analysis of safety, effectiveness and compliance of EPO (erythropoietin) therapy by using WEPOXÂ® Dispopen 20,000 IU, A new delivery device, in the management of CKD Anemia - AWAKE

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2022/07/043917

Enrollment

1500

Registered

2022-07-12

Start date

Unknown

Completion date

Unknown

Last updated

2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D758- Other specified diseases of bloodand blood-forming organs

Interventions

Intervention1: WEPOXÂ® Dispopen 20,000 IU: 25-100 IU/kg, three times in a week, Subcutaneous route for 3 months Control Intervention1: NOT APPLICABLE: NOT APPLICABLE Control Intervention2: NA: NA

Eligibility

Inclusion criteria

Inclusion criteria: Patients newly prescribed with WEPOX Dispopen 20000 IU for anemia due to chronic kidney disease (CKD) Patient willing to comply with the protocol and written Informed Consent

Exclusion criteria

Exclusion criteria: Patients who do not meet requirement as per prescribing information of WEPOX Dispopen 20000 IU Pregnant and lactating females

Design outcomes

Primary

Measure	Time frame
Safety of WEPOX Dispopen 20000 IUTimepoint: Baseline and Day 90Â±7 (visit 2)	—

Secondary

Measure	Time frame
Rise in Hemoglobin (Hb) levelsTimepoint: Day 0 and Day 90	—

Countries

India

Contacts

Public ContactDr Khokan Debnath

Wockhardt Ltd.

skamble@wockhardt.com9167723490

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026